Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588622 | 0.86 | PNMT (0.52) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| SCHEMBL30331914 | 0.86 | PNMT (0.52) | HTR2CPNMTCD44MAOBHTR2A | |
| SCHEMBL12822 | 0.86 | PNMT (0.52) | HTR2CPNMTCD44MAOBHTR2A | |
| Hydrochloric Acid SCHEMBL2378664 | 0.84 | PNMT (0.50) | HTR2CPNMTCD44MAOBPOLB | |
| Hydrochloric Acid SCHEMBL6607726 | 0.84 | PNMT (0.50) | HTR2CPNMTCD44MAOBPOLB | |
| Hydrochloric Acid SCHEMBL15410642 | 0.84 | PNMT (0.50) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| Hydrochloric Acid SCHEMBL12985101 | 0.84 | PNMT (0.50) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| SCHEMBL8348677 | 0.80 | — | — | |
| SCHEMBL17413659 | 0.80 | DRD2 (0.42) | HTR2CHTR2ACHRM1HTR2BDRD2 | |
| Bromide SCHEMBL8777272 | 0.78 | DRD2 (0.41) | HTR2CHTR2ACHRM1HTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390623-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | PFIZER INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11390623-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | PFIZER INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11001698-B2 | Stabilizer composition | BASF SE | 2021-05-11 | — | — | US | disclosed |
| CN-108147994-B | Key intermediate of 6,7,8, 9-tetrahydro-5H-pyrido [2,3-d ] azepine and preparation method thereof | 南京药石科技股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-108147994-B | Key intermediate of 6,7,8, 9-tetrahydro-5H-pyrido [2,3-d ] azepine and preparation method thereof | 南京药石科技股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-108147994-B | Key intermediate of 6,7,8, 9-tetrahydro-5H-pyrido [2,3-d ] azepine and preparation method thereof | 南京药石科技股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| EP-3402796-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS | PFIZER (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3402796-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS | PFIZER (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008009125-A9 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | NPS ALLELIX CORP (CA) | 2008-07-24 | — | — | WO | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008009125-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | HTR2C 3446/4885CHRNB2 2785/4885CHRNA4 3379/4885 |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | HTR2C 1/4885CHRNB2 69/4885CHRNA4 38/4885 |
| US-11390623-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | DRD3, DRD2, DRD4 | HTR2C 18/4885CHRNB2 64/4885CHRNA4 26/4885 |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | HTR2C 3446/4885CHRNB2 2785/4885CHRNA4 3379/4885 |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | HTR2C 3370/4885CHRNB2 1408/4885CHRNA4 1629/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | HTR2C 1035/4885CHRNB2 1365/4885CHRNA4 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.